AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients

AstraZeneca Plc AZN reported initial data from the TROPION-PanTumor01 Phase 1 trial of datopotamab deruxtecan (Dato-DXd).
The data showed encouraging and durable efficacy in patients with heavily pretreated hormone receptor (HR)-positive, HER2-low, or HER2-negative (IHC 0) unresectable or metastatic breast cancer.
Safety results were consistent with previous trials of datopotamab deruxtecan.
Also see: AstraZeneca Highlights Detailed Data From Two Breast Cancer Trials.
In this cohort of TROPION-PanTumor01 (n=41), datopotamab deruxtecan demonstrated an objective response rate (ORR) of 27%.
All responses were partial (n=11), and 56% of patients achieved stable disease (n=23).
The disease control rate (DCR) was 85%, and the median progression-free survival (PFS) was 8.3 months.
With a median follow-up of 13.7 months, the median duration of response (DoR) and the median overall survival (OS) had not been reached, with 59% of patients alive for more than one year.
Pivotal TROPION-Breast01 Phase 3 trial is ongoing, evaluating datopotamab deruxtecan in these patients in earlier lines of treatment.
Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody-drug conjugate (ADC) jointly developed by Daiichi Sankyo DSNKY and AstraZeneca.
Price Action: AZN shares closed higher by 0.46% at $69.17 on Thursday.
Photo Via Wikimedia Commons